Navigation Links
Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week
Date:1/31/2011

BEVERLY HILLS, Calif., Jan. 31, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX™ joint health formula, launched commercially in December 2010.  Specifically, the study found that reduction of pain was statistically significant after as little as one week of ERGOFLEX use.  Similar improvements were seen with range of motion.  Benefits continued during the six weeks subjects took ERGOFLEX, and for some the benefits persisted during the subsequent six-week washout period.

ERGOFLEX is the only joint health complex containing the powerful antioxidant L-Ergothioneine (ERGO) and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health. It is the first in a series of products built around the ERGO platform that are planned by OXIS.  

"These powerful and statistically significant final results strongly suggest that ERGOFLEX can provide significant quick and lasting relief from mild-to-moderate joint pain while improving range of motion, which results in an improved quality of life," said Bernie Landes, President of OXIS International.  "These clinically demonstrated results represent an important breakthrough for those tens of millions of Americans who suffer with chronic joint pain and diminished range of motion.  While most joint pain products only address the symptoms, ERGOFLEX targets and relieves oxidative stress, which frequently is the underlying cause of joint ailments. It also provides a suite of extensively researched natural ingredients that help maintain the structural integrity of joints and relieve pain."

The study included 12 subjects ta
'/>"/>

SOURCE OXIS International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  IBM (NYSE: IBM ... ( DESY ), a leading national research center in ... and storage of massive volumes of x-ray data. The ... on IBM software defined technology can handle more than ... and help scientists worldwide gain faster insights into the ...
(Date:8/21/2014)... -- Seventy-one percent of Americans believe the abuse of strong prescription ... and safety issue in the United States ... Repass & Partners, a Cincinnati based ... of the prescription medication abuse problem and the need for ... situation facing our country," Rex Repass , CEO of ...
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... Health Organization has issued a warning to medical travelers: ... heels of a growing threat of an antibiotic-resistant superbug, ... the region in India where it was discovered. "Many ... or knee replacements, ACL surgeries, root canals and spinal ...
...  Neuro Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers ... test for vestibular and neurological conditions, said today ... control and analysis software at the upcoming annual ... Boston ( http://am2010.entnet.org/ ). NKI will ...
Cached Medicine Technology:New York Plastic Surgery News: Medical Tourists Beware of Drug-Resistant Superbug NDM-1 2Neuro Kinetics to Showcase Enhanced Control & Analysis Software at Otolaryngology Conference 2
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... developed by Dr. Sen and Dr. Samantha Pearson to ... glasses, contacts, and avoid corrective vision surgery by instead ... Shane Michaels, prompting an investigative review. , “There’s ... billions of dollars in revenue each year—it’s because people ...
(Date:8/22/2014)... August 22, 2014 Testosterone treatment ... in U.S. courts on behalf of men who ... use of prescription low testosterone therapies, Bernstein Liebhard ... claim was filed against Pfizer Inc. on July ... life-threatening heart issues due to his use of ...
(Date:8/22/2014)... du Sac, Wisconsin (PRWEB) August 22, 2014 ... PFTape™ System for Plantar Fasciitis, an exciting new product ... product allows you to stay active while you heal. ... application. This is truly a new technology – it ... and affordable. , FasciaDerm® PFTape™ System for Plantar ...
(Date:8/22/2014)... The improved access to antiretroviral drugs and treatments ... has led to the decline in the rate of ... AIDS globally. However, despite the fact that HIV infection ... affected by the virus is on the rise. With ... organisations and stakeholders, by 2015, significant investments are expected ...
(Date:8/22/2014)... News) -- Back-to-school time provides an opportunity for parents ... family schedules, an expert suggests. "Forget New Year,s ... also be the start of a new fitness and ... kinesiology at the University of the Sciences in Philadelphia, ... extracurricular activities likely to build up, "it,s important for ...
Breaking Medicine News(10 mins):Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:With Kids in School, Parents Can Work Out 2
... HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay News) ... with standard care, omega-3 fatty acid supplements appear to ... "Adding n-3 polyunsaturated fatty acids, even in patients ... a further improvement in heart function and exercise capacity," ...
... WEDNESDAY, Jan. 5 (HealthDay News) -- Women with multiple sclerosis ... a gene thought to be connected to the condition, a ... gain more insight into the development of MS, which is ... women. Although no one knows what causes MS, scientists suspect ...
... By Alan Mozes HealthDay Reporter , ... suggests that cocaine addiction might be treatable with a ... common cold virus in combination with a cocaine-like substance ... vaccine appears to provoke an effective and long-lasting antibody ...
... RI When methicillin-resistant S. aureus (MRSA) is ... for an invasive infection, including a surgical site infection. Some ... in the nose, the greater the risk of transmission to ... Few studies to date have assessed the differences in quantity ...
... 2011A new, simplified method for producing large amounts of ... cells will help advance the promising field of gene ... human clinical trials. The novel adeno-associated virus (AAV) production ... ahead of publication in Human Gene Therapy , ...
... News) -- Stress can cause even a healthy cat to ... researchers found that healthy cats were just as likely as ... waste outside their litter box if there was a change ... or caretaker. The healthy cats were compared to cats ...
Cached Medicine News:Health News:Fish Oil May Help Some Heart Failure Patients 2Health News:Fish Oil May Help Some Heart Failure Patients 3Health News:Study Sheds Light on Genetic Risk of MS 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 3Health News:Where MRSA colonizes on the human body 2Health News:Faster, scalable method for producing AAV-based gene transfer vectors 2
... Finnpipette BioControl multichannel has ... as the single channel ... fits all seven multichannel ... tip cone modules. Both ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... a 384 Well Plate at Once , To ... you need a pipettor that can adapt to ... get with our 16-channel Impact pipettor., Available with ... was specifically designed to allow you to transfer ...
Medicine Products: